Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02256553
Recruitment Status : Completed
First Posted : October 3, 2014
Results First Posted : January 18, 2016
Last Update Posted : March 3, 2017
Sponsor:
Information provided by (Responsible Party):
ALK-Abelló A/S

Brief Summary:
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass [Phleum pratense] extract, SCH 697243, GRASTEK®) sublingual tablets co-administered in participants 18 through 65 years of age with both ragweed- and grass polled-induced allergic rhinitis, with or without conjunctivitis and with or without asthma. The primary endpoint is the percentage of participants who experience at least one event of local swelling after co-administration of MK-3641 and MK-7243 sublingual tablets.

Condition or disease Intervention/treatment Phase
Rhinitis, Allergic, Seasonal Biological: MK-3641 12 Amb a 1-U (short ragweed extract) Biological: MK-7243 2800 BAU (Timothy grass extract) Drug: Rescue Medication Phase 4

Detailed Description:
Events of local swelling include pharyngeal edema, laryngeal edema, mouth edema, oropharyngeal swelling, palatal edema, tongue swelling/edema or throat tightness.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 102 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis
Study Start Date : October 2014
Actual Primary Completion Date : February 2015
Actual Study Completion Date : February 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pinkeye
Drug Information available for: MK 7243

Arm Intervention/treatment
Experimental: MK-3641+ MK-7243
Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
Biological: MK-3641 12 Amb a 1-U (short ragweed extract)
12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
Other Names:
  • SCH 039641
  • RAGWITEK®

Biological: MK-7243 2800 BAU (Timothy grass extract)
2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
Other Names:
  • SCH 697243
  • GRASTEK®

Drug: Rescue Medication
Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.




Primary Outcome Measures :
  1. Percentage of Participants Who Experienced at Least One Event of Local Swelling [ Time Frame: During Period I, Period II and Period III (Up to 6 weeks) ]
    Events of local swelling included pharyngeal edema, laryngeal edema, mouth edema, oropharyngeal swelling, palatal edema, tongue swelling/edema, or throat tightness. Events that occurred during in-clinic dosing were to be monitored and recorded by clinic staff. A Side Effect Report Card was used in Periods I-III to collect information on adverse events identified by the World Allergy Organization (WAO) as local side effects of sublingual immunotherapy (SLIT) that occurred within the first 60 minutes after study drug intake. During Period I, participants were to complete the report card once a day after MK-7243 was administered. During Period II, participants were to complete the report card twice a day, once after each tablet was administered. During Period III, participants were to complete the report card once a day after both tablets were administered.


Secondary Outcome Measures :
  1. Percentage of Participants Who Experienced at Least One Event of Local Application Site Reaction [ Time Frame: During Period I, Period II and Period III (Up to 6 weeks) ]
    Events of local application site reactions included pharyngeal edema, laryngeal edema, mouth edema, oropharyngeal swelling, palatal edema, tongue swelling/edema, throat tightness, lip swelling/edema, ear pruritus, dysphagia, oral discomfort, glossodynia, oral pruritus, hypoaesthesia oral, throat irritation, paraesthesia oral or stomatitis. Events that occurred during in-clinic dosing were to be monitored and recorded by clinic staff. A Side Effect Report Card was used in Periods I-III to collect information on adverse events identified by the WAO as local side effects of SLIT that occurred within the first 60 minutes after study drug intake. During Period I, participants were to complete the report card once a day after MK-7243 was administered. During Period II, participants were to complete the report card twice a day, once after each tablet was administered. During Period III, participants were to complete the report card once a day after both tablets were administered.

  2. Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE) [ Time Frame: During Period I, Period II and Period III (Up to 6 weeks) ]
    An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, was also an AE.

  3. Percentage of Participants Who Experienced at Least One Local Application Site Reaction That Required Symptomatic Treatment [ Time Frame: During Period I, Period II and Period III (Up to 6 weeks) ]
    Events of local application site reactions included pharyngeal edema, laryngeal edema, mouth edema, oropharyngeal swelling, palatal edema, tongue swelling/edema, throat tightness, lip swelling/edema, ear pruritus, dysphagia, oral discomfort, glossodynia, oral pruritus, hypoaesthesia oral, throat irritation, paraesthesia oral or stomatitis. Events that occurred during in-clinic dosing were to be monitored and recorded by clinic staff. A Side Effect Report Card was used in Periods I-III to collect information on adverse events identified by the WAO as local side effects of SLIT that occurred within the first 60 minutes after study drug intake. During Period I, participants were to complete the report card once a day after MK-7243 was administered. During Period II, participants were to complete the report card twice a day, once after each tablet was administered. During Period III, participants were to complete the report card once a day after both tablets were administered.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical history of physician-diagnosed ragweed- and grass pollen-induced rhinitis with or without conjunctivitis of >1 year duration, with or without asthma
  • Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Randomization Visits and must agree to remain abstinent or use (or have their partner use) any one of the acceptable methods of birth control within the projected duration of the study. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy, hormonal contraception.

Exclusion Criteria:

  • Unstable, uncontrolled or severe asthma treated with long-acting beta agonists (LABAs) at the time of Screening
  • Received immunosuppressive treatment within 3 months prior to Randomization (except steroids for allergic reactions other than asthma)
  • History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, unknown cause, or inhalant allergen
  • Diagnosis of eosinophilic esophagitis
  • History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy
  • Female and breastfeeding, pregnant or intending to become pregnant
  • Received another form of allergen immunotherapy with the past month
  • Previously exposed to MK-3641 (RAGWITEK®) or other sublingual ragweed immunotherapy
  • Previously exposed to MK-7243 (GRASTEK®) or other sublingual grass immunotherapy
  • Known history of allergy, hypersensitivity, or intolerance to the excipient ingredients of the study drug (except for Ambrosia artemisiifolia and/or Phleum pratense), or self-injectable epinephrine
  • Unable to or will not comply with the use of self-injectable epinephrine
  • Used an investigational drug within 30 days prior to Screening Visit, or plans to participate in another interventional clinical trial during the duration of this trial
  • Family member of the investigational or sponsor staff involved in this trial
  • Participating in this same trial at another investigational site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02256553


Sponsors and Collaborators
ALK-Abelló A/S
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.

Publications of Results:
Layout table for additonal information
Responsible Party: ALK-Abelló A/S
ClinicalTrials.gov Identifier: NCT02256553    
Other Study ID Numbers: P08607
First Posted: October 3, 2014    Key Record Dates
Results First Posted: January 18, 2016
Last Update Posted: March 3, 2017
Last Verified: January 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases